Virbac confirms 2026 outlook for Virbac stock

Published on 10/01/2026 at 14:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac stock costs EUR 308.75 on October 1, 2026 after EUR 311.00, minus 0.72 percent. First-half revenue reached EUR 768.0 million, up 7.40 percent.

Schwarzweißes Reportagefoto eines Veterinärlabors mit Forschern bei der Arbeit — Dokumentarische Schwarzweiß-Reportage über Virbac S.A., Aktie FR0000031577, zeigt ein modernes Labor der Tiergesundheitsbranche, Illustration mit AI erstellt.

Virbac (ISIN FR0000031577) was trading at EUR 308.75 at Lang & Schwarz on October 1, 2026 at 2:39 p.m. CEST, down 0.72 percent from the prior close of EUR 311.00. On September 17, 2026, Virbac confirmed its 2026 outlook at the upper end of a 5.50 to 7.50 percent revenue-growth range at constant exchange rates and scope.

Half-year growth supports guidance

First-half 2026 revenue reached EUR 768.0 million, representing growth of 7.40 percent at constant exchange rates and scope compared with the first half of 2025. Reuters reported on September 17, 2026 that recurring operating profit excluding acquisition amortization increased to EUR 144.2 million from EUR 135.0 million in the first half of 2025.

The company reported an adjusted EBIT margin of 18.80 percent for the first half of 2026, up from 18.30 percent in the comparable period. Consolidated net income rose 5.90 percent to EUR 87.1 million, while companion-animal revenue grew 10.00 percent and farm-animal revenue increased 6.70 percent.

Margin and balance sheet matter

The result gives Virbac more room to pursue its 2026 plan while keeping the operating target visible. The company expects an adjusted recurring operating income margin of 17.00 percent for the full year and said first-half momentum positions revenue growth at the upper end of its range.

Financial discipline remains a counterweight to the growth figures. Net debt stood at EUR 196 million at June 2026, compared with EUR 173 million at December 2025, while first-half capital spending reached EUR 57.3 million. Virbac also highlighted its Supercharge platforms, which grew 12.00 percent at constant exchange rates excluding Thyronorm.

Stock remains below yearly high

Virbac trades on Euronext Paris under ticker VIRP, according to FT.com. The finance quote shows a EUR 297.00 to EUR 389.50 52-week range and market capitalization of EUR 2.6 billion as of October 1, 2026, placing the Lang & Schwarz price above the yearly low but below the high.

At Lang & Schwarz, Virbac was trading intraday at EUR 308.75 on October 1, 2026 at 2:39 p.m. CEST. The price was down 0.72 percent versus the Lang & Schwarz prior close of EUR 311.00.